GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » EBITDA Margin %

Hainan Poly Pharm Co (SZSE:300630) EBITDA Margin % : 28.00% (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hainan Poly Pharm Co's EBITDA for the three months ended in Sep. 2023 was ¥145 Mil. Hainan Poly Pharm Co's Revenue for the three months ended in Sep. 2023 was ¥518 Mil. Therefore, Hainan Poly Pharm Co's EBITDA margin for the quarter that ended in Sep. 2023 was 28.00%.


Hainan Poly Pharm Co EBITDA Margin % Historical Data

The historical data trend for Hainan Poly Pharm Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Poly Pharm Co EBITDA Margin % Chart

Hainan Poly Pharm Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.16 39.53 43.59 39.68 32.70

Hainan Poly Pharm Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.26 -13.70 39.52 32.87 28.00

Competitive Comparison of Hainan Poly Pharm Co's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Poly Pharm Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Poly Pharm Co's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Poly Pharm Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Hainan Poly Pharm Co's EBITDA Margin % falls into.



Hainan Poly Pharm Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Hainan Poly Pharm Co's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=590.63/1806.345
=32.70 %

Hainan Poly Pharm Co's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=145.092/518.194
=28.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Poly Pharm Co  (SZSE:300630) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Hainan Poly Pharm Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Poly Pharm Co (SZSE:300630) Business Description

Traded in Other Exchanges
N/A
Address
No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051
Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.
Executives
Fan De Zhu Independent director
Xie Hui Fang Supervisors
Pu Jian Executives
Xu Zhao Securities Affairs Representative
Shen Shi Hua Executives
Zhou Mao Directors, Directors, and Executives

Hainan Poly Pharm Co (SZSE:300630) Headlines

No Headlines